Cultural Foundation
Author:
Spyre Therapeutics, Inc.
Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock
April 14, 2026
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
April 13, 2026
Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
April 13, 2026
Spyre Therapeutics Announces Grants of Inducement Awards
April 3, 2026
Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026
March 16, 2026